Clearside Biomedical, Inc.: insider trades · United States · SEC (Form 4)

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ market under ticker CLSDQ. The company is headquartered in Alpharetta, Georgia, United States. Its core focus is ophthalmology, specifically the delivery of therapies to the back of the eye through the suprachoroidal space, using a proprietary platform known as SCS® (Suprachoroidal Space) and the SCS Microinjector®. For French, Belgian, and Swiss investors, Clearside should be viewed as a specialist platform company rather than a diversified large-cap pharma group: its value proposition is built on targeted drug delivery to the macula, retina, and choroid. Founded in the mid-2010s, Clearside developed its strategy around an office-based, repeatable, non-surgical injection procedure designed to place medication closer to diseased tissue in retinal and choroidal disorders. Its first commercial product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, received U.S. FDA approval in October 2021 and is available in the United States through a commercial partner. That approval matters strategically because it validated the company’s platform at both the regulatory and clinical levels, even though commercialization remains limited and dependent on partner execution. Clearside’s lead development asset is CLS-AX (axitinib injectable suspension), a phase 3-ready program being advanced in wet age-related macular degeneration (wet AMD), one of the largest therapeutic markets in ophthalmology. The company also emphasizes strategic collaborations with third parties that use its suprachoroidal delivery technology to support other ophthalmic innovations. This platform approach is a potential competitive advantage because it can extend the SCS technology across multiple compounds and partners, while reducing the company’s reliance on a single asset. Competitively, Clearside operates in a field dominated by established intravitreal injection standards and, depending on the indication, by well-known anti-VEGF and corticosteroid therapies. As a result, the investment case depends on clinical differentiation, procedural convenience, and eventual adoption by retina specialists. Geographically, the company’s footprint is primarily U.S.-centric, with research, corporate, and commercialization activities centered in the United States and with market access driven mainly through partnerships rather than a large direct-sales infrastructure. Recent developments have been important for investors. In 2025, Clearside highlighted CLS-AX and its SCS platform at specialist medical meetings. At the same time, SEC filings indicated major corporate restructuring steps, including exploration of strategic alternatives and, later, actions related to Nasdaq delisting and termination of registration. In other words, Clearside combines a scientifically interesting ophthalmic delivery platform with a much more complex and higher-risk financial and market backdrop than a mature commercial biopharma company.